

**Drug Utilization Review (DUR) Meeting Minutes**  
**September 3, 2020**

**Members Present:** Andrea Honeyman, Mary Aaland, Joshua Askvig, Gabriela Balf, Jennifer Iverson, Katie Kram, Cory Miller, Laura Schield, Tanya Schmidt, Amy Werremeyer, Peter Woodrow

**Medicaid Pharmacy Department:** Alexi Murphy, Brendan Joyce, LeNeika Roerich

**Old Business**

Chair A. Honeyman called the meeting to order at 1:01 p.m. B. Joyce announced the appointment of Joshua Askvig to the DUR Board. Chair A. Honeyman asked for a motion to approve the minutes of the June meeting. K. Kram moved that the minutes be approved, and P. Woodrow seconded the motion. The chair called for a voice vote to approve the minutes. The motion passed with no audible dissent. B. Joyce presented the quarterly budget update to the DUR Board.

**Review Top 25 Drugs**

T. DeRuiter and B. Joyce presented the quarterly review of the top 25 drugs based on total cost of claims, as well as the top AHFS drug classes by cost and claims count based on the total number of claims for the 2nd quarter of 2020.

**PDL/PA Criteria Updates**

A. Murphy presented the updates and changes to medications requiring prior authorization to the Board since the most recent version of the Preferred Drug List was posted. Changes included additions to the PA criteria approved by the Board at the prior DUR Board meeting, as well as adding new agents and formulations to prior authorization class criteria, where applicable. Notable changes included Nurtec ODT, Reyvow, Ajovy, Harvoni Pallet, and Sovaldi Pallet being added require prior authorization, as well as Harvoni 45 mg/200mg tablet and Sovaldi 200 mg tablet being added to the preferred list of Hepatitis C treatment agents. All PDL updates are listed in the handouts for the June 2020 DUR Board meeting. When a new version of the PDL is published and posted to the website, all updates/changes made since the last version are called out at the top of the document itself.

**Second Review of Palforzia**

A motion and second was made at the June 2020 DUR Board meeting to place Palforzia on prior authorization. The topic was brought up for a second review. Prior authorization criteria were presented to the Board by T. DeRuiter. S. Payne from Aimmune made herself available to the Board for questions. During Board discussion, M. Aaland requested that the Prior Authorization request forms be changed from "to be completed by physician", to make the request forms more accurate. P. Woodrow made a motion that the state amend and update the prior authorization request forms accordingly to reflect that the forms may be filled out by prescribers or their representatives at the states discretion, and K. Kram seconded the motion. The chair called for a voice vote to approve the motion to update the request forms, which passed without audible dissent. Chair A. Honeyman called for a voice vote to approve the criteria, which passed with no audible dissent.

### **Second Review of Mytesi**

A motion and second was made at the June 2020 DUR Board meeting to place Mytesi on prior authorization. The topic was brought up for a second review. Prior authorization criteria were presented to the Board by T. DeRuiter. There were no public comments. Chair A. Honeyman called for a voice vote to approve the updated criteria, which passed with no audible dissent.

### **Second Review of Antifibrinolytic Agents**

A motion and second was made at the June 2020 DUR Board meeting to place antifibrinolytic agents on prior authorization. The topic was brought up for a second review. Prior authorization criteria were presented to the Board by T. DeRuiter. There were no public comments. Chair A. Honeyman called for a voice vote to approve the updated criteria, which passed with no audible dissent.

### **Second Review of ACL Inhibitors**

A motion and second was made at the June 2020 DUR Board meeting to place the ACL inhibitors on prior authorization. The topic was brought up for a second review. T. DeRuiter presented Prior authorization criteria for all lipid lowering agents that combines previously approved prior authorization criteria for lipid lowering agents with new prior authorization criteria for ACL inhibitors. There were no public comments. Chair A. Honeyman called for a voice vote to approve the updated criteria, which passed with no audible dissent.

### **Second Review of Cystic Fibrosis Agents (CFTR Inhibitors)**

A motion and second was made at the June 2020 DUR Board meeting to place CFTR inhibitors for cystic fibrosis on prior authorization. The topic was brought up for a second review. Prior authorization criteria were presented to the Board by T. DeRuiter. There were no public comments. Chair A. Honeyman called for a voice vote to approve the updated criteria, which passed with no audible dissent.

### **New Business**

#### **Review of Agents for the Treatment of Diabetic Gastroparesis**

T. DeRuiter presented a review of agents for the treatment of diabetic gastroparesis to the Board.. A motion was made by A. Werremeyer to manage this class of medications through prior authorization. The motion was seconded by L. Schield. Prior authorization criteria for these agents will be presented, reviewed, and voted on by the Board at the next meeting.

#### **Review of Oriahnn**

T. DeRuiter a review of Oriahnn to the Board. During public comment, J. Gianninoto from Abbvie presented an overview of clinical information to the Board. During Board discussion, G. Balf requested that future pricing data also reflect the cost of treatment over a period of time as opposed to just cost per package or unit cost. T. DeRuiter agreed to add this information to future presentations. A motion was made by P. Woodrow to manage this medication through prior authorization. The motion was seconded by K. Kram. Prior authorization criteria for these agents will be presented, reviewed, and voted on by the Board at the next meeting.

### **Review of Dojolvi**

T. DeRuiter and A. Murphy presented a review of antifibrinolytic agents to the Board. During public comment, T. Arnhart Rusinak from Ultragenyx presented an overview of clinical information on Dojolvi to the Board, including explaining the difference between Dojolvi and medical foods. A motion was made by K. Kram to manage this agent through prior authorization. The motion was seconded by A. Werremeyer. Prior authorization criteria for these agents will be presented, reviewed, and voted on by the Board at the next meeting.

### **Report on Utilization of Benzodiazepines and Opioids Concurrently**

Since 2017, North Dakota Medicaid has put claims processing edits and prior authorization criteria on skeletal muscle relaxants to promote safe and effective use of these agents. T. DeRuiter presented utilization data comparing the use of skeletal muscle relaxants in 2017 vs 2020, including total patient and prescription counts during this time. The data showed that use of all skeletal muscle relaxants other than orphenadrine has been lowered since implementing these utilization requirements, with the largest drop being in cyclobenzaprine utilization.

North Dakota Medicaid implemented prior authorization class criteria for topical steroids in 2017. T. DeRuiter presented utilization data comparing the use of topical corticosteroids by potency class in 2017 vs 2018 (after criteria had been implemented), including total prescription counts and claims cost information. The data showed that utilization in each potency category remained roughly the same in 2018 as in 2017, however claims cost was reduced in each category (16%-38% reduction in cost by potency category and overall claims cost reduction of ~25%).

### **Retrospective Drug Utilization Review (RDUR) Criteria Recommendations**

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and are consistent with new indications, new drugs added, and new warnings. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. M. Aaland moved to approve the new criteria and L. Schield seconded the motion. The motion passed with no audible dissent.

### **Adjournment and Upcoming Meeting Date**

K. Kram made a motion to adjourn, which was seconded by A. Werremeyer. Chair A. Honeyman adjourned the meeting at 3:00 pm. The next DUR Board meeting will be held December 2, 2020 at 1:00 pm via teleconference.